Back to top

Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics today and set a price target of $35.00. The company’s shares c...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nurix Therapeutics, Inc. (NRIX)